The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10317 malaria professionals are enjoying the free benefits of MalariaWorld today

in vivo

Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models

February 11, 2020 - 16:23 -- Open Access
Author(s): 
Marco Tamborrini, Julia Hauser, Anja Schäfer, Mario Amacker, Paola Favuzza, Kwak Kyungtak, Sylvain Fleury, Gerd Pluschke
Reference: 
NPJ Vaccines. 2020; 5:9

The Plasmodium falciparum (Pf) cysteine-rich protective antigen (PfCyRPA) has emerged as a promising blood-stage candidate antigen for inclusion into a broadly cross-reactive malaria vaccine. This highly conserved protein among various geographical strains plays a key role in the red blood cell invasion process by P. falciparum merozoites, and antibodies against PfCyRPA can efficiently prevent the entry of the malaria parasites into red blood cells.

In Vivo Activity of Amodiaquine against Ebola Virus Infection

January 15, 2020 - 07:58 -- Open Access
Author(s): 
DeWald LE, Johnson JC, Gerhardt DM, Torzewski LM, Postnikova E, Honko AN, Janosko K, Huzella L, Dowling WE, Eakin AE, Osborn BL, Gahagen J, Tang L, Green CE, Mirsalis JC, Holbrook MR, Jahrling PB, Dyall J, Hensley LE
Reference: 
Scientific Reports, 2019 Dec 27; 9(1):20199

During the Ebola virus disease (EVD) epidemic in Western Africa (2013‒2016), antimalarial treatment was administered to EVD patients due to the high coexisting malaria burden in accordance with World Health Organization guidelines. In an Ebola treatment center in Liberia, EVD patients receiving the combination antimalarial artesunate-amodiaquine had a lower risk of death compared to those treated with artemether-lumefantrine.

Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages

December 23, 2019 - 15:05 -- Open Access
Author(s): 
Yevel Flores-Garcia, Sonia M. Herrera, Hugo Jhun, Daniel W. Pérez-Ramos, C. Richter King, Emily Locke, Ramadevi Raghunandan and Fidel Zavala
Reference: 
Malaria Journal 2019 18:426, 18 December 2019

The circumsporozoite protein (CSP) of Plasmodium is a key surface antigen that induces antibodies and T-cells, conferring immune protection in animal models and humans. However, much of the work on CSP and immunity has been developed based on studies using rodent or non-human primate CSP antigens, which may not be entirely translatable to CSP expressed by human malaria parasites, especially considering the host specificity of the different species.

Mode of action of quinoline antimalarial drugs in red blood cells infected by Plasmodium falciparum revealed in vivo

November 18, 2019 - 16:15 -- Open Access
Author(s): 
Sergey Kapishnikov, Trine Staalsø, Yang Yang, Jiwoong Lee, Ana J. Pérez-Berná, Eva Pereiro, Yang Yang, Stephan Werner, Peter Guttmann, Leslie Leiserowitz, and Jens Als-Nielsen
Reference: 
PNAS November 12, 2019 116 (46) 22946-22952

The most widely used antimalarial drugs belong to the quinoline family. Their mode of action has not been characterized at the molecular level in vivo. We report the in vivo mode of action of a bromo analog of the drug chloroquine in rapidly frozen Plasmodium falciparum-infected red blood cells.

Medical Condition: 
Subscribe to RSS - in vivo